Taylor P. GSK, J&J say monthly injection keeps HIV controlled. PMLiVE 2019:8 de marzo. [Ref.ID 103051]

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

Muanda FT, Sheehy O, Bérard A. Use of trimethoprim–sulfamethoxazole during pregnancy and risk of spontaneous abortion: a nested case control study. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102803]

Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018:24 de julio. [Ref.ID 102748]

Rasmussen SA, Barfield W, Honein MA. Protecting mothers and babies — A delicate balancing act. N Engl J Med 2018:24 de julio. [Ref.ID 102747]

Anónimo. “Mosaic” HIV vaccine triggers immune response in people in clinical trial. DIA Daily 2018:1. [Ref.ID 102710]

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]

Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]

Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

Anónimo. Rilpivirine et HIV chez les adolescents. Prescrire 2017;37:13-4. [Ref.ID 101362]

Almendrala A. The success of HIV treatment is increasing the risk of drug-resistance. And the threat is growing.. The Huffington Post 2016:1. [Ref.ID 100995]

Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn G, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jacoki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun T-W. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N Engl J Med 2016:9 de noviembre. [Ref.ID 100922]

Anónimo. UK appeals court rules NHS has authority to fund PrEP medication for HIV. DIA Daily 2016:1. [Ref.ID 100918]

Anónimo. Various states approve recreational, medical marijuana use. DIA Daily 2016:7. [Ref.ID 100907]

Anónimo. Impact of two cases of HIV among PrEP-using patients overblown, HIV experts say. DIA Daily 2016:4. [Ref.ID 100885]

Anónimo. Patients worldwide turning to “buyers clubs” for access to hepatitis C, HIV medications. DIA Daily 2016:7. [Ref.ID 100881]

Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]

Anónimo. UK court rules that NHS can fund HIV PrEP drug. DIA Daily 2016:1. [Ref.ID 100564]